<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602445</url>
  </required_header>
  <id_info>
    <org_study_id>HSFO-000524</org_study_id>
    <secondary_id>20120208-01H</secondary_id>
    <nct_id>NCT01602445</nct_id>
  </id_info>
  <brief_title>Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism</brief_title>
  <acronym>REMARK</acronym>
  <official_title>Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The presence of clots in the veins of arms and/or legs or lungs of Cancer patients decreases
      their quality of life, delays their treatment and may cause death. The best way to avoid new
      clots is by giving blood thinners before clots are formed, but even some patients who are
      taking blood thinners may form blood clots. A major problem is that it is difficult to know
      which patients form clots while they are receiving blood thinners, a situation called
      treatment failure. Several studies have shown that by doing blood tests that measure the
      formation of clots, the investigators could know if the patient is responding to the blood
      thinners. If this is proven, the investigators will be able to apply these tests to all
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic failure in cancer patients at high risk for recurrence of Venous thromboembolism
      (VTE) may be as high as 20% and the risk of death from a recurrent episode of pulmonary
      embolism is at least 8%. Studies that have used pro-coagulant and thrombin generation markers
      support the notion that cancer is associated with a hypercoagulability state and that
      intensified doses of anticoagulation may be necessary to suppress this state. Thus, it may be
      possible that by using these tests, we would identify the patients that do not respond to
      standard doses of anticoagulation. To date, only few small studies have evaluated the use of
      pro-coagulant markers in cancer patients but this data is promising. Our study will measure
      pro-coagulant markers in cancer patients at risk for VTE recurrence to determine if there is
      a relationship between the changes in the levels of pro-coagulant markers and VTE recurrence
      while taking anticoagulation with low-molecular weight-heparin (LMWH). The evaluation of the
      pro-coagulant markers may enable new treatment strategies in cancer patients who fail their
      initial treatment. Patients will be stratified by a risk model developed by our group and
      will be validate with this study. This new approach has the potential to improve the recovery
      of patients, to reduce death and disability due to clots in the veins of legs or arms and/or
      lungs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative changes on biochemical markers</measure>
    <time_frame>at initiation of anticoagulation (baseline); at 7-14 days; 21-35 days; 37- 44 days; 83-97 days; and 173-187 days after initiation of anticoagulation.</time_frame>
    <description>The following pro-coagulant and thrombin-generation markers will be measured:
Prothrombin fragments F1+2;
D-dimer,
thrombin-antithrombin (TAT)
Soluble P-selectin.
For each patient, we will calculate baseline values and the relative changes (delta) of procoagulant and thrombin generation markers. The relative changes (delta) will be defined by the percentage of change in the marker at each visit relative to baseline measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of treatment failure</measure>
    <time_frame>6 months</time_frame>
    <description>This outcome will be measured by the proportion of cancer patients who might develop recurrent VTE while on 6-month treatment with anticoagulation within the time-frame of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between treatment failure and markers</measure>
    <time_frame>6 months after treatment failure</time_frame>
    <description>This outcome will be assessed by determining the best cutoff for each marker that would correctly classify success or failure to anticoagulation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to anticoagulation treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Compliance to medication will be measured by review of the patient medication diary.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep-Vein Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer patients</arm_group_label>
    <description>All cancer patients with a diagnosed acute symptomatic VTE episode.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum specimens Optional DNA banking
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Referrals of cancer patients to the Thrombosis clinic at each participating center at the
        time that an acute episode of VTE has been confirmed ( within 0 +/- 1 day) from the start
        of anticoagulation treatment. Our centers provide VTE treatment for all the cancer patients
        in our regions given the design of the Ontario Cancer Program, ensuring a generalizable
        patient population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with any type of cancer (except basal cell and squamous cell carcinoma of the
             skin) and at any stage of the disease or treatment

          -  Confirmed newly diagnosed acute symptomatic VTE (proximal DVT, PE, Arm DVT, Multiple
             SSPE only)

          -  Planned treatment of VTE with low-molecular weight heparin (LMWH)

          -  Age 18 years old or older.

        Exclusion Criteria:

          -  Planned cell transplant

          -  Patient receiving anticoagulation due to other clinical indications

          -  Patient who has received more than one therapeutic dose of LMWH

          -  Unable or unwilling to provide written, informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip S Wells, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Health District Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Science Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Notre-Dame Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010 Apr 13;102 Suppl 1:S2-9. doi: 10.1038/sj.bjc.6605599. Review.</citation>
    <PMID>20386546</PMID>
  </reference>
  <reference>
    <citation>Blom JW, Vanderschoot JP, OostindiÃ«r MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006 Mar;4(3):529-35.</citation>
    <PMID>16460435</PMID>
  </reference>
  <reference>
    <citation>Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 Nov 15;100(10):3484-8. Epub 2002 Jul 12.</citation>
    <PMID>12393647</PMID>
  </reference>
  <reference>
    <citation>Coleman R, MacCallum P. Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer. 2010 Apr 13;102 Suppl 1:S17-23. doi: 10.1038/sj.bjc.6605601. Review.</citation>
    <PMID>20386545</PMID>
  </reference>
  <reference>
    <citation>Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10;349(2):146-53.</citation>
    <PMID>12853587</PMID>
  </reference>
  <reference>
    <citation>Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 2002 Aug;88(2):213-20.</citation>
    <PMID>12195692</PMID>
  </reference>
  <reference>
    <citation>Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA, Eichinger S. The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. Thromb Haemost. 2010 Jul;104(1):92-9. doi: 10.1160/TH09-12-0863. Epub 2010 May 10.</citation>
    <PMID>20458441</PMID>
  </reference>
  <reference>
    <citation>Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer. 2008 Oct 7;99(7):1000-6. doi: 10.1038/sj.bjc.6604620. Epub 2008 Sep 2.</citation>
    <PMID>18766191</PMID>
  </reference>
  <results_reference>
    <citation>Louzada ML, Carrier M, Lazo-Langner A, Dao V, Zhang J, Kovacs MJ, Lee AY, Levine MN, Meyer G, Rodger M, Wells PS. Validation of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. American Society of Hematology, 52nd Annual Meeting, Orlando Florida, December 4-7, 2010. Abstract 4209. Poster Board III-988.</citation>
  </results_reference>
  <results_reference>
    <citation>Louzada ML, Lazo-Langner A, Dao V, Zhang J, Kovacs MJ, Carrier M, Wells PS. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. American Society of Hematology, 52nd Annual Meeting, Orlando, Florida, December 4-7, 2010. Abstract 475.</citation>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous Thrombosis</keyword>
  <keyword>Coagulation factors</keyword>
  <keyword>Cancer</keyword>
  <keyword>Blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

